A 75-year-old woman presenting with decreased visual acuity and metamorphopsia in the right eye was referred for further evaluation of a pigmented epiretinal membrane. She had a history of cutaneous nodular melanoma in the right arm. Tumor staging was classified as T3N0M0 in August 2017, at the time of diagnosis and excision. In April 2018, axillary lymphadenectomy was performed for local recurrence and the patient started treatment with an immune checkpoint inhibitor (ICI) pembrolizumab, without further local or metastatic evidence of the tumor. Ocular history was positive for cataract surgery bilaterally. After cataract surgery in the right eye, an asymptomatic vision loss was noted and the cause was attributed to the presence of choroidal neovascularization (CNV), for which the patient underwent intravitreal anti–vascular endothelial growth factor (anti-VEGF) injections.
Please finish quiz first before checking answer.
Read the answer below and download your certificate.
Read the discussion below and retake the quiz.
Cutaneous melanoma metastatic to the vitreous cavity and deposition of melanoma cells over the epiretinal membrane
C. Perform pars plana vitrectomy and excisional biopsy of the membrane
The patient underwent diagnostic and therapeutic pars plana vitrectomy (Figure 2) during which vitreous biopsy and epiretinal membrane peeling were performed. Pathology and immunohistochemistry of the membrane and cytology of the vitreous confirmed the diagnosis of metastatic cutaneous melanoma (CM) (Figure 2).
Metastasis is the most common intraocular neoplasia and is most commonly associated with primary breast and lung tumors; however, the eye is an unusual site for CM metastasis, and when it occurs, the most common site of involvement is the choroid.1,2 In contrast, the vitreous is an exceptionally rare site of metastasis for any cancer, including CM. A large recent multicenter case series revealed that the median age at presentation for vitreous CM metastasis was 66 years, the median time from starting immunotherapy to ocular symptoms was 17 months, and 10 of 11 patients were treated with ICIs at some point in the treatment course.2 This is consistent with our case findings.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: André Borges Silva, MD, Centro Hospitalar Tondela-Viseu, Av. Rei Dom Duarte, 3504-509 Viseu, Portugal (firstname.lastname@example.org).
Published Online: October 13, 2022. doi:10.1001/jamaophthalmol.2022.3949
Conflict of Interest Disclosures: Dr Figueira reported nonfinancial support from Alcon and Roche and personal fees from AbbVie, Alimera, Novartis, and Bayer outside the submitted work. No other disclosures were reported.
Additional Contributions: We thank Miguel Ribeiro, MD, for the patient referral, Nuno Gouveia, MD, who helped capture the optical coherence tomography and fundus images in the Ophthalmology Department, and Graça Fernandes, MD, and Barbara Sepodes, MD, who provided the photomicrograph showing cytopathologic results of epiretinal membrane biopsy sample. We also thank the patient for granting permission to publish this information.
You currently have no searches saved.
You currently have no courses saved.